Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria)

  1. Ritthideach Yorsaeng
  2. Preeyaporn Vichaiwattana
  3. Sirapa Klinfueng
  4. Lakkhana Wongsrisang
  5. Natthinee Sudhinaraset
  6. Sompong Vongpunsawad
  7. Yong Poovorawan
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Limited COVID-19 vaccines in many countries have delayed mass-immunization. Although individuals fully vaccinated with Vaxzevria (AstraZeneca) have higher antibody levels than those with CoronaVac (Sinovac), heterologous prime-boost with CoronaVac-Vaxzevria yielded comparable antibody levels to two-dose Vaxzevria. Combination use of different available vaccines may be warranted in Thailand, which faces limited vaccine choice and supply.

Related articles

Related articles are currently not available for this article.